
<document id="DBMI.pac155" origId="pac155">
	<sentence id="DBMI.pac155.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP."/>
	<sentence id="DBMI.pac155.s1" origId="s1" text="Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation."/>
	<sentence id="DBMI.pac155.s2" origId="s2" text="In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentence id="DBMI.pac155.s3" origId="s3" text="Studies in vitro have shown that sildenafil is selective for PDE5."/>
	<sentence id="DBMI.pac155.s4" origId="s4" text="Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11)."/>
	<sentence id="DBMI.pac155.s5" origId="s5" text="The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentence id="DBMI.pac155.s6" origId="s6" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina."/>
	<sentence id="DBMI.pac155.s7" origId="s7" text="This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]."/>
	<sentence id="DBMI.pac155.s8" origId="s8" text="In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentence id="DBMI.pac155.s9" origId="s9" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo."/>
	<sentence id="DBMI.pac155.s10" origId="s10" text="12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg)."/>
	<sentence id="DBMI.pac155.s11" origId="s11" text="The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentence id="DBMI.pac155.s12" origId="s12" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range."/>
	<sentence id="DBMI.pac155.s13" origId="s13" text="Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]."/>
	<sentence id="DBMI.pac155.s14" origId="s14" text="Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentence id="DBMI.pac155.s15" origId="s15" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported."/>
	<sentence id="DBMI.pac155.s16" origId="s16" text="After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s17" origId="s17" text="After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentence id="DBMI.pac155.s18" origId="s18" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg)."/>
	<sentence id="DBMI.pac155.s19" origId="s19" text="Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels."/>
	<sentence id="DBMI.pac155.s20" origId="s20" text="This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentence id="DBMI.pac155.s21" origId="s21" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry."/>
	<sentence id="DBMI.pac155.s22" origId="s22" text="12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%)."/>
	<sentence id="DBMI.pac155.s23" origId="s23" text="Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentence id="DBMI.pac155.s24" origId="s24" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%."/>
	<sentence id="DBMI.pac155.s25" origId="s25" text="The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues."/>
	<sentence id="DBMI.pac155.s26" origId="s26" text="Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentence id="DBMI.pac155.s27" origId="s27" text="Protein binding is independent of total drug concentrations."/>
	<sentence id="DBMI.pac155.s28" origId="s28" text="Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes."/>
	<sentence id="DBMI.pac155.s29" origId="s29" text="The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentence id="DBMI.pac155.s30" origId="s30" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug."/>
	<sentence id="DBMI.pac155.s31" origId="s31" text="In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects."/>
	<sentence id="DBMI.pac155.s32" origId="s32" text="In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentence id="DBMI.pac155.s33" origId="s33" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours."/>
	<sentence id="DBMI.pac155.s34" origId="s34" text="After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose)."/>
	<sentence id="DBMI.pac155.s35" origId="s35" text="REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentence id="DBMI.pac155.s36" origId="s36" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose."/>
	<sentence id="DBMI.pac155.s37" origId="s37" text="Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s38" origId="s38" text="The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentence id="DBMI.pac155.s39" origId="s39" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH."/>
	<sentence id="DBMI.pac155.s40" origId="s40" text="In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers."/>
	<sentence id="DBMI.pac155.s41" origId="s41" text="There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s42" origId="s42" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers."/>
	<sentence id="DBMI.pac155.s43" origId="s43" text="Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years)."/>
	<sentence id="DBMI.pac155.s44" origId="s44" text="Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentence id="DBMI.pac155.s45" origId="s45" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered."/>
	<sentence id="DBMI.pac155.s46" origId="s46" text="In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment."/>
	<sentence id="DBMI.pac155.s47" origId="s47" text="In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentence id="DBMI.pac155.s48" origId="s48" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment."/>
	<sentence id="DBMI.pac155.s49" origId="s49" text="Patients with severe hepatic impairment (Child-Pugh class C) have not been studied."/>
	<sentence id="DBMI.pac155.s50" origId="s50" text="Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentence id="DBMI.pac155.s51" origId="s51" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance."/>
	<sentence id="DBMI.pac155.s52" origId="s52" text="Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M)."/>
	<sentence id="DBMI.pac155.s53" origId="s53" text="Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8637" id="DBMI.pac155.s53.e0" origId="s53.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="8770-8781" id="DBMI.pac155.s53.e1" origId="s53.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.s53.e0" e2="DBMI.pac155.s53.e1" id="DBMI.pac155.s53.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.s53.e1" e2="DBMI.pac155.s53.e0" id="DBMI.pac155.s53.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s54" origId="s54" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone."/>
	<sentence id="DBMI.pac155.s55" origId="s55" text="This is consistent with ritonavir's marked effects on a broad range of P450 substrates."/>
	<sentence id="DBMI.pac155.s56" origId="s56" text="Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9157" id="DBMI.pac155.s56.e0" origId="s56.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9238-9249" id="DBMI.pac155.s56.e1" origId="s56.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s56.e0" e2="DBMI.pac155.s56.e1" id="DBMI.pac155.s56.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s56.e1" e2="DBMI.pac155.s56.e0" id="DBMI.pac155.s56.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s57" origId="s57" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors."/>
	<sentence id="DBMI.pac155.s58" origId="s58" text="Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID."/>
	<sentence id="DBMI.pac155.s59" origId="s59" text="This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentence id="DBMI.pac155.s60" origId="s60" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.">
		<entity charOffset="9791-9802" id="DBMI.pac155.s60.e0" origId="s60.e0" text="Cimetidine " type="Active ingredient"/>
		<entity charOffset="9873-9884" id="DBMI.pac155.s60.e1" origId="s60.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s60.e0" e2="DBMI.pac155.s60.e1" id="DBMI.pac155.s60.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac155.s60.e1" e2="DBMI.pac155.s60.e0" id="DBMI.pac155.s60.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s61" origId="s61" text="When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).">
		<entity charOffset="10033-10046" id="DBMI.pac155.s61.e0" origId="s61.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="10136-10147" id="DBMI.pac155.s61.e1" origId="s61.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s61.e0" e2="DBMI.pac155.s61.e1" id="DBMI.pac155.s61.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac155.s61.e1" e2="DBMI.pac155.s61.e0" id="DBMI.pac155.s61.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s62" origId="s62" text="In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10265-10276" id="DBMI.pac155.s62.e0" origId="s62.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="10394-10405" id="DBMI.pac155.s62.e1" origId="s62.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s62.e0" e2="DBMI.pac155.s62.e1" id="DBMI.pac155.s62.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.s62.e1" e2="DBMI.pac155.s62.e0" id="DBMI.pac155.s62.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s63" origId="s63" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration."/>
	<sentence id="DBMI.pac155.s64" origId="s64" text="Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax.">
		<entity charOffset="10714-10725" id="DBMI.pac155.s64.e0" origId="s64.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="11010-11019" id="DBMI.pac155.s64.e1" origId="s64.e1" text="bosentan " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s64.e0" e2="DBMI.pac155.s64.e1" id="DBMI.pac155.s64.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
		<pair e1="DBMI.pac155.s64.e1" e2="DBMI.pac155.s64.e0" id="DBMI.pac155.s64.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
	</sentence>
	<sentence id="DBMI.pac155.s65" origId="s65" text="Co-administration resulted in a 50% increase in AUC of bosentan."/>
	<sentence id="DBMI.pac155.s66" origId="s66" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing)."/>
	<sentence id="DBMI.pac155.s67" origId="s67" text="Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil."/>
	<sentence id="DBMI.pac155.s68" origId="s68" text="Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11364-11377" id="DBMI.pac155.s68.e0" origId="s68.e0" text="epoprostenol " type="Active ingredient"/>
		<entity charOffset="11297-11308" id="DBMI.pac155.s68.e1" origId="s68.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s68.e0" e2="DBMI.pac155.s68.e1" id="DBMI.pac155.s68.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="epoprostenol "/>
		<pair e1="DBMI.pac155.s68.e1" e2="DBMI.pac155.s68.e0" id="DBMI.pac155.s68.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s69" origId="s69" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant."/>
	<sentence id="DBMI.pac155.s70" origId="s70" text="The effect of sildenafil on epoprostenol pharmacokinetics is not known."/>
	<sentence id="DBMI.pac155.s71" origId="s71" text="CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentence id="DBMI.pac155.s72" origId="s72" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates.">
		<entity charOffset="11970-11981" id="DBMI.pac155.s72.e0" origId="s72.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12085-12095" id="DBMI.pac155.s72.e1" origId="s72.e1" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="12070-12081" id="DBMI.pac155.s72.e2" origId="s72.e2" text="saquinavir " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s72.e0" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e1" e2="DBMI.pac155.s72.e2" id="DBMI.pac155.s72.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e0" id="DBMI.pac155.s72.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s72.e2" e2="DBMI.pac155.s72.e1" id="DBMI.pac155.s72.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s73" origId="s73" text="No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9."/>
	<sentence id="DBMI.pac155.s74" origId="s74" text="Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="12333-12351" id="DBMI.pac155.s74.e0" origId="s74.e0" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12425-12436" id="DBMI.pac155.s74.e1" origId="s74.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12362-12377" id="DBMI.pac155.s74.e2" origId="s74.e2" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s74.e0" e2="DBMI.pac155.s74.e1" id="DBMI.pac155.s74.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="ethinyl estradiol "/>
		<pair e1="DBMI.pac155.s74.e0" e2="DBMI.pac155.s74.e2" id="DBMI.pac155.s74.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e1" e2="DBMI.pac155.s74.e0" id="DBMI.pac155.s74.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e1" e2="DBMI.pac155.s74.e2" id="DBMI.pac155.s74.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e2" e2="DBMI.pac155.s74.e0" id="DBMI.pac155.s74.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s74.e2" e2="DBMI.pac155.s74.e1" id="DBMI.pac155.s74.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="levonorgestrel "/>
	</sentence>
	<sentence id="DBMI.pac155.s75" origId="s75" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg).">
		<entity charOffset="12437-12448" id="DBMI.pac155.s75.e0" origId="s75.e0" text="Sildenafil " type="Active ingredient"/>
		<entity charOffset="12536-12551" id="DBMI.pac155.s75.e1" origId="s75.e1" text="levonorgestrel " type="Active ingredient"/>
		<entity charOffset="12507-12525" id="DBMI.pac155.s75.e2" origId="s75.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.s75.e0" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e1" e2="DBMI.pac155.s75.e2" id="DBMI.pac155.s75.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e0" id="DBMI.pac155.s75.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s75.e2" e2="DBMI.pac155.s75.e1" id="DBMI.pac155.s75.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac155.s76" origId="s76" text="Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin.">
		<entity charOffset="12630-12641" id="DBMI.pac155.s76.e0" origId="s76.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12727-12740" id="DBMI.pac155.s76.e1" origId="s76.e1" text="atorvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s76.e0" e2="DBMI.pac155.s76.e1" id="DBMI.pac155.s76.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.s76.e1" e2="DBMI.pac155.s76.e0" id="DBMI.pac155.s76.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="atorvastatin "/>
	</sentence>
	<sentence id="DBMI.pac155.s77" origId="s77" text="Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12777-12797" id="DBMI.pac155.s77.e0" origId="s77.e0" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="12855-12866" id="DBMI.pac155.s77.e1" origId="s77.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12797-12816" id="DBMI.pac155.s77.e2" origId="s77.e2" text="aluminum hydroxide " type="Active ingredient"/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac155.s77.e0" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e1" e2="DBMI.pac155.s77.e2" id="DBMI.pac155.s77.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e0" id="DBMI.pac155.s77.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.s77.e2" e2="DBMI.pac155.s77.e1" id="DBMI.pac155.s77.p5" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="aluminum hydroxide "/>
	</sentence>
	<sentence id="DBMI.pac155.s78" origId="s78" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg)."/>
	<sentence id="DBMI.pac155.s79" origId="s79" text="Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%."/>
	<sentencespan id="DBMI.pac155.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation."/>
	<sentencespan id="DBMI.pac155.sp1" origId="sp1" text="Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility."/>
	<sentencespan id="DBMI.pac155.sp2" origId="sp2" text="Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels [see Clinical Pharmacology (12.2)]. In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets."/>
	<sentencespan id="DBMI.pac155.sp3" origId="sp3" text="The inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo. 12.2 Pharmacodynamics\n\nEffects of REVATIO on Blood Pressure\n\nSingle oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 12 hours after dosing, and was not different from placebo at 8 hours."/>
	<sentencespan id="DBMI.pac155.sp4" origId="sp4" text="Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)]. Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG."/>
	<sentencespan id="DBMI.pac155.sp5" origId="sp5" text="After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported. After chronic dosing of 80 mg TID sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively. After chronic dosing of 80 mg TID sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively."/>
	<sentencespan id="DBMI.pac155.sp6" origId="sp6" text="After chronic dosing of 80 mg TID sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg). Effects of REVATIO on Vision\n\nAt single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina."/>
	<sentencespan id="DBMI.pac155.sp7" origId="sp7" text="An evaluation of visual function at doses up to 200 mg revealed no effects of REVATIO on visual acuity, intraocular pressure, or pupillometry. 12.3 Pharmacokinetics\n\nAbsorption and Distribution\n\nREVATIO is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (2563%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state."/>
	<sentencespan id="DBMI.pac155.sp8" origId="sp8" text="When REVATIO is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins."/>
	<sentencespan id="DBMI.pac155.sp9" origId="sp9" text="Protein binding is independent of total drug concentrations. Metabolism and Excretion\n\nSildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized."/>
	<sentencespan id="DBMI.pac155.sp10" origId="sp10" text="This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher."/>
	<sentencespan id="DBMI.pac155.sp11" origId="sp11" text="Both sildenafil and the active metabolite have terminal half-lives of about 4 hours. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). REVATIO Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration."/>
	<sentencespan id="DBMI.pac155.sp12" origId="sp12" text="A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose. Population Pharmacokinetics\n\nAge, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function."/>
	<sentencespan id="DBMI.pac155.sp13" origId="sp13" text="None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH. In patients with PAH, the average steady-state concentrations were 2050% higher when compared to those of healthy volunteers. There was also a doubling of Cmin levels compared to healthy volunteers."/>
	<sentencespan id="DBMI.pac155.sp14" origId="sp14" text="Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with pulmonary hypertension compared to healthy volunteers. Geriatric Patients\n\nHealthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (1845 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively."/>
	<sentencespan id="DBMI.pac155.sp15" origId="sp15" text="Renal Impairment\n\nIn volunteers with mild (CLcr = 5080 mL/min) and moderate (CLcr = 3049 mL/min) renal impairment, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr &lt; 30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and Cmax compared to age-matched volunteers with no renal impairment. In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased 200 % and 79 %, respectively, in subjects with severe renal impairment compared to subjects with normal renal function."/>
	<sentencespan id="DBMI.pac155.sp16" origId="sp16" text="Hepatic Impairment\n\nIn volunteers with mild to moderate hepatic cirrhosis (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) compared to age-matched volunteers with no hepatic impairment. Patients with severe hepatic impairment (Child-Pugh class C) have not been studied. Drug Interaction Studies\n\nSildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms."/>
	<sentencespan id="DBMI.pac155.sp17" origId="sp17" text="Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance. Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 &gt;150 M). Ritonavir and other CYP3A Inhibitors\n\nIn study in healthy volunteers, co-administration with ritonavir, a potent CYP3A inhibitor, at steady state (500 mg BID) with sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma AUC.">
		<entity charOffset="8627-8637" id="DBMI.pac155.sp17.e0" origId="sp17.e0" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="8770-8781" id="DBMI.pac155.sp17.e1" origId="sp17.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.sp17.e0" e2="DBMI.pac155.sp17.e1" id="DBMI.pac155.sp17.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="ritonavir "/>
		<pair e1="DBMI.pac155.sp17.e1" e2="DBMI.pac155.sp17.e0" id="DBMI.pac155.sp17.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp18" origId="sp18" text="At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Although the interaction between other protease inhibitors (except saquinavir) and REVATIO has not been studied, their concomitant use is expected to increase sildenafil levels.">
		<entity charOffset="9146-9157" id="DBMI.pac155.sp18.e0" origId="sp18.e0" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9238-9249" id="DBMI.pac155.sp18.e1" origId="sp18.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp18.e0" e2="DBMI.pac155.sp18.e1" id="DBMI.pac155.sp18.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp18.e1" e2="DBMI.pac155.sp18.e0" id="DBMI.pac155.sp18.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp19" origId="sp19" text="Population data from patients in clinical trials indicated a reduction in sildenafil clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir)."/>
	<sentencespan id="DBMI.pac155.sp20" origId="sp20" text="Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC). In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.">
		<entity charOffset="10033-10046" id="DBMI.pac155.sp20.e0" origId="sp20.e0" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="10136-10147" id="DBMI.pac155.sp20.e1" origId="sp20.e1" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="10265-10276" id="DBMI.pac155.sp20.e2" origId="sp20.e2" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="9791-9802" id="DBMI.pac155.sp20.e3" origId="sp20.e3" text="Cimetidine " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="erythromycin "/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e0" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e1" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p7" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p8" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="saquinavir "/>
		<pair e1="DBMI.pac155.sp20.e2" e2="DBMI.pac155.sp20.e3" id="DBMI.pac155.sp20.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e0" id="DBMI.pac155.sp20.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e1" id="DBMI.pac155.sp20.p11" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="Cimetidine "/>
		<pair e1="DBMI.pac155.sp20.e3" e2="DBMI.pac155.sp20.e2" id="DBMI.pac155.sp20.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp21" origId="sp21" text="REVATIO Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration. Bosentan\n\nIn a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg TID) with bosentan (a moderate inducer of CYP3A, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg BID) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil Cmax. Co-administration resulted in a 50% increase in AUC of bosentan.">
		<entity charOffset="10714-10725" id="DBMI.pac155.sp21.e0" origId="sp21.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="11010-11019" id="DBMI.pac155.sp21.e1" origId="sp21.e1" text="bosentan " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp21.e0" e2="DBMI.pac155.sp21.e1" id="DBMI.pac155.sp21.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="bosentan " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p1" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
		<pair e1="DBMI.pac155.sp21.e1" e2="DBMI.pac155.sp21.e0" id="DBMI.pac155.sp21.p2" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="bosentan "/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp22" origId="sp22" text="The combination of both drugs did not lead to clinically significant changes in blood pressure (supine or standing). Concomitant administration of potent CYP3A inducers is expected to cause greater decreases in plasma levels of sildenafil. Epoprostenol\n\nThe mean reduction of sildenafil (80 mg tid) bioavailability due to co-administration of epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations.">
		<entity charOffset="11364-11377" id="DBMI.pac155.sp22.e0" origId="sp22.e0" text="epoprostenol " type="Active ingredient"/>
		<entity charOffset="11297-11308" id="DBMI.pac155.sp22.e1" origId="sp22.e1" text="sildenafil " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp22.e0" e2="DBMI.pac155.sp22.e1" id="DBMI.pac155.sp22.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="sildenafil " precipitant="epoprostenol "/>
		<pair e1="DBMI.pac155.sp22.e1" e2="DBMI.pac155.sp22.e0" id="DBMI.pac155.sp22.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp23" origId="sp23" text="Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known. CYP Substrates and Beta-blockers\n\nPopulation pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance or an increase of oral bioavailability when co-administered with CYP3A substrates and the combination of CYP3A substrates and beta-blockers."/>
	<sentencespan id="DBMI.pac155.sp24" origId="sp24" text="In a study of healthy volunteers, sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, both of which are CYP3A substrates. No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. Oral Contraceptives\n\nConcomitant administration of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg) did not affect the pharmacokinetics of sildenafil.">
		<entity charOffset="11970-11981" id="DBMI.pac155.sp24.e0" origId="sp24.e0" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12085-12095" id="DBMI.pac155.sp24.e1" origId="sp24.e1" text="ritonavir " type="Active ingredient"/>
		<entity charOffset="12070-12081" id="DBMI.pac155.sp24.e2" origId="sp24.e2" text="saquinavir " type="Active ingredient"/>
		<entity charOffset="12333-12351" id="DBMI.pac155.sp24.e3" origId="sp24.e3" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12362-12377" id="DBMI.pac155.sp24.e4" origId="sp24.e4" text="levonorgestrel " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ritonavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="saquinavir " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e0" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e1" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e2" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p12" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="ethinyl estradiol "/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e3" e2="DBMI.pac155.sp24.e4" id="DBMI.pac155.sp24.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e0" id="DBMI.pac155.sp24.p16" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="levonorgestrel "/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e1" id="DBMI.pac155.sp24.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e2" id="DBMI.pac155.sp24.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp24.e4" e2="DBMI.pac155.sp24.e3" id="DBMI.pac155.sp24.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp25" origId="sp25" text="Sildenafil had no impact on the plasma levels of oral contraceptives (ethinyl estradiol 30 mcg and levonorgestrel 150 mcg). Atorvastatin\n\nConcomitant administration of a single 100 mg dose of sildenafil with 10 mg of atorvastatin did not alter the pharmacokinetics of either sildenafil or atorvastatin. Antacids\n\nSingle doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of sildenafil.">
		<entity charOffset="12437-12448" id="DBMI.pac155.sp25.e0" origId="sp25.e0" text="Sildenafil " type="Active ingredient"/>
		<entity charOffset="12536-12551" id="DBMI.pac155.sp25.e1" origId="sp25.e1" text="levonorgestrel " type="Active ingredient"/>
		<entity charOffset="12507-12525" id="DBMI.pac155.sp25.e2" origId="sp25.e2" text="ethinyl estradiol " type="Active ingredient"/>
		<entity charOffset="12630-12641" id="DBMI.pac155.sp25.e3" origId="sp25.e3" text="sildenafil " type="Active ingredient"/>
		<entity charOffset="12727-12740" id="DBMI.pac155.sp25.e4" origId="sp25.e4" text="atorvastatin " type="Active ingredient"/>
		<entity charOffset="12777-12797" id="DBMI.pac155.sp25.e5" origId="sp25.e5" text="magnesium hydroxide " type="Active ingredient"/>
		<entity charOffset="12797-12816" id="DBMI.pac155.sp25.e6" origId="sp25.e6" text="aluminum hydroxide " type="Active ingredient"/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="levonorgestrel " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p1" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="ethinyl estradiol " precipitant="Sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p2" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e0" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p7" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p8" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p9" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p10" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e1" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p11" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p12" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p13" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p14" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p15" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p16" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e2" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p17" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p18" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p19" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p20" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p21" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="atorvastatin " precipitant="sildenafil "/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p22" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e3" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p23" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p24" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p25" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p26" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p27" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="atorvastatin "/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p28" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e4" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p29" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p30" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p31" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p32" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p33" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="magnesium hydroxide "/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p34" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e5" e2="DBMI.pac155.sp25.e6" id="DBMI.pac155.sp25.p35" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e0" id="DBMI.pac155.sp25.p36" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e1" id="DBMI.pac155.sp25.p37" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e2" id="DBMI.pac155.sp25.p38" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e3" id="DBMI.pac155.sp25.p39" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="sildenafil " precipitant="aluminum hydroxide "/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e4" id="DBMI.pac155.sp25.p40" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac155.sp25.e6" e2="DBMI.pac155.sp25.e5" id="DBMI.pac155.sp25.p41" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac155.sp26" origId="sp26" text="Aspirin\n\nSildenafil (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Alcohol\n\nSildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%."/>
</document>
